A Diabetes (Type 1 & 2) programme at an EU clinic such as our partner Stem Plus (Sofia) is typically €3,000–€8,000 for treatment — a fraction of US or German pricing, at full European GMP standards. Some patients access treatment at no cost through one of the 236 registered Diabetes (Type 1 & 2) trials — see the candidacy check first.
Type 1 and Type 2 diabetes both involve dysfunction of insulin-producing beta cells — Type 1 through autoimmune destruction, Type 2 through insulin resistance and beta-cell exhaustion. Stem-cell research targets both: placental mesenchymal stem cells and fetal-derived stem cells are studied for their potential to differentiate toward insulin-producing cells, support pancreatic tissue, and dampen autoimmunity. In Type 1 the immune-modulating properties may restrain beta-cell attack; in Type 2 the aim is to ease insulin resistance and support residual reserve. Translating stem-cell-derived beta cells into safe, scalable, durable treatment remains a major unsolved scientific challenge, and all current clinical work is early-stage.
Indicative European costs are roughly €4,000–€8,000 per course, reflecting cell expansion, purity testing, and frequently multiple infusions. Type 1 protocols may add immune-monitoring; Type 2 protocols often bundle metabolic assessment and follow-up. For context, insulin and monitoring supplies cost roughly €100–€300 monthly and are proven — the stem-cell figure is indicative and unproven.
Two hundred thirty-six registered trials and 26 recruiting studies address stem-cell therapy in diabetes — the largest trial landscape among the conditions here. Small cohorts report modest improvements in insulin secretion and HbA1c, but quality is heterogeneous and controls are often absent. Some report temporary reductions in insulin requirement; durability beyond 12 months is poorly documented. No trial has produced insulin independence in Type 1, and sustained insulin-free control in Type 2 is rare.
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | EU · GMP |
| Germany | €15,000–35,000 | EU · premium |
| USA | €18,000–35,000 | Mostly investigational |
| Serbia (e.g. Swiss Medica) | €7,000–31,000 | Non-EU |
| Mexico | €3,000–12,000 | Non-EU |
| Turkey / Thailand | €5,000–18,000 | Non-EU |
Bulgaria's price reflects lower operating cost inside the same EU GMP framework as Germany — not lower quality. Cell type, number of sessions and supportive care move where a Diabetes (Type 1 & 2) programme sits in the €3,000–€8,000 range; you receive a fixed written quote after a medical review. The cheapest monitored route of all is a registered clinical trial — check before paying privately. Watch for hidden "cell-expansion" or repeat-cycle fees billed separately.
Lower operating cost and jurisdiction — not lower quality. Bulgaria is a full EU member, so cells are prepared to the same GMP standard as Germany, but clinic overheads and salaries are far lower. That gap, not a quality compromise, is where the saving comes from.
Cheaper is not automatically riskier — but unregulated is. The real test is GMP certification, a certified cell bank and EU oversight, which the EU provides. Be wary of ultra-low prices from clinics that will not document their laboratory or their cells.
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
A fixed written quote follows a medical review of your records — so there are no surprise charges later.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估